Literature DB >> 18802090

Disruption of allergenic activity of the major grass pollen allergen Phl p 2 by reassembly as a mosaic protein.

Nadine Mothes-Luksch1, Sabine Stumvoll, Birgit Linhart, Margit Focke, Marie-Therese Krauth, Alexander Hauswirth, Peter Valent, Petra Verdino, Tea Pavkov, Walter Keller, Monika Grote, Rudolf Valenta.   

Abstract

The recognition of conformational epitopes on respiratory allergens by IgE Abs is a key event in allergic inflammation. We report a molecular strategy for the conversion of allergens into vaccines with reduced allergenic activity, which is based on the reassembly of non-IgE-reactive fragments in the form of mosaic proteins. This evolution process is exemplified for timothy grass pollen-derived Phl p 2, a major allergen for more than 200 million allergic patients. In a first step, the allergen was disrupted into peptide fragments lacking IgE reactivity. cDNAs coding for these peptides were reassembled in altered order and expressed as a recombinant mosaic molecule. The mosaic molecule had lost the three-dimensional structure, the IgE reactivity, and allergenic activity of the wild-type allergen, but it induced high levels of allergen-specific IgG Abs upon immunization. These IgG Abs crossreacted with group 2 allergens from other grass species and inhibited allergic patients' IgE binding to the wild-type allergen. The mosaic strategy is a general strategy for the reduction of allergenic activity of protein allergens and can be used to convert harmful allergens into safe vaccines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18802090     DOI: 10.4049/jimmunol.181.7.4864

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergy.

Authors:  Birgit Linhart; Margarete Focke-Tejkl; Milena Weber; Meena Narayanan; Angela Neubauer; Hannes Mayrhofer; Katharina Blatt; Christian Lupinek; Peter Valent; Rudolf Valenta
Journal:  J Immunol       Date:  2015-03-18       Impact factor: 5.422

Review 2.  Utility and Comparative Efficacy of Recombinant Allergens Versus Allergen Extract.

Authors:  Hardik D Patel; Jeffrey M Chambliss; Meera R Gupta
Journal:  Curr Allergy Asthma Rep       Date:  2017-08-18       Impact factor: 4.806

Review 3.  Recombinant Allergens in Structural Biology, Diagnosis, and Immunotherapy.

Authors:  Angelika Tscheppe; Heimo Breiteneder
Journal:  Int Arch Allergy Immunol       Date:  2017-05-04       Impact factor: 2.749

4.  Incorporation of T-cell epitopes from tetanus and diphtheria toxoids into in-silico-designed hypoallergenic vaccine may enhance the protective immune response against allergens.

Authors:  Ali Ghasemi; Reza Falak; Mohsen Mohammadi; Soheila June Maleki; Mohamad-Ali Assarezadegan; Mojtaba Jafary
Journal:  Iran J Basic Med Sci       Date:  2020-05       Impact factor: 2.699

Review 5.  Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives.

Authors:  Birgit Linhart; Rudolf Valenta
Journal:  Vaccine       Date:  2011-11-17       Impact factor: 3.641

6.  Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.

Authors:  Margarete Focke-Tejkl; Milena Weber; Katarzyna Niespodziana; Angela Neubauer; Hans Huber; Rainer Henning; Gottfried Stegfellner; Bernhard Maderegger; Martina Hauer; Frank Stolz; Verena Niederberger; Katharina Marth; Julia Eckl-Dorna; Richard Weiss; Josef Thalhamer; Katharina Blatt; Peter Valent; Rudolf Valenta
Journal:  J Allergy Clin Immunol       Date:  2014-11-13       Impact factor: 10.793

Review 7.  Egg Allergy: Diagnosis and Immunotherapy.

Authors:  Dulashi Withanage Dona; Cenk Suphioglu
Journal:  Int J Mol Sci       Date:  2020-07-16       Impact factor: 5.923

8.  Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction.

Authors:  M Curin; M Weber; T Thalhamer; I Swoboda; M Focke-Tejkl; K Blatt; P Valent; K Marth; T Garmatiuk; H Grönlund; J Thalhamer; S Spitzauer; R Valenta
Journal:  Clin Exp Allergy       Date:  2014-06       Impact factor: 5.018

9.  Dissection of the IgE and T-cell recognition of the major group 5 grass pollen allergen Phl p 5.

Authors:  Margarete Focke-Tejkl; Raffaela Campana; Renate Reininger; Christian Lupinek; Katharina Blatt; Peter Valent; Tea Pavkov-Keller; Walter Keller; Rudolf Valenta
Journal:  J Allergy Clin Immunol       Date:  2013-10-31       Impact factor: 10.793

Review 10.  Multiple grass mixes as opposed to single grasses for allergen immunotherapy in allergic rhinitis.

Authors:  K Gangl; V Niederberger; R Valenta
Journal:  Clin Exp Allergy       Date:  2013-11       Impact factor: 5.018

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.